Eton Pharmaceuticals, Inc.
ETON
Positions held
Your positionsETON isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Eton Pharmaceuticals operates in the specialty drug manufacturing sector, which is experiencing significant growth due to increasing demand for innovative therapies.
- Revenue increased by 55% compared to the prior quarter, reaching $38 million.
- Gross margin improved to 67.6%, up from 60.7% in the previous quarter.
- The company's operating margin remains under pressure, indicating potential challenges in cost management and profitability.
- Eton reported a net income of $1.554 million in Q1 2026, a significant drop from the previous quarter's $11.578 million.
- The overall trend shows a neutral score of 9.00, with indicators suggesting a potential pullback in stock performance.
Fundamentals
| Market cap | $1.56B | Enterprise value | $1.57B | Trailing P/E | 136.88 | Forward P/E | 21.22 |
| PEG | — | Price / book | 33.24 | Beta | 0.90 | Dividend yield | 0.00% |
| Revenue growth | 98.6% | Earnings growth | — | Gross margin | 61.4% | Operating margin | 35.8% |
| Profit margin | 12.0% | ROE | 36.0% | ROA | 11.9% | Debt / equity | 0.63 |
| Current ratio | 1.52 | Free cash flow | $6.58M | Analyst recommendation | strong_buy | Mean target | $71.00 |
| 52w high | $66.37 | 52w low | $14.27 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $37.6M | $24.3M | $21.3M | $22.5M | $18.9M | — |
| Op margin | 34.0% | 9.9% | 11.6% | -6.1% | -7.8% | — |
| Net income | $11.6M | $1.6M | $1.5M | -$1.9M | -$2.6M | — |
| Gross margin | 67.6% | 60.7% | 61.6% | 35.0% | 63.0% | — |
| Gross profit | $25.4M | $14.7M | $13.1M | $7.9M | $11.9M | — |
| Operating income | $12.8M | $2.4M | $2.5M | -$1.4M | -$1.5M | — |
- Revenue +55% vs prior quarter ($38M vs $24M).
- Gross margin 67.6% (was 60.7% prior quarter).
- Operating margin expanded to 34%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $80.0M | $39.0M | $31.6M | $21.3M | — |
| Op margin | -1.1% | -6.7% | -3.8% | -38.9% | — |
| Net income | -$4.6M | -$3.8M | -$0.9M | -$9.0M | — |
| Gross margin | 53.5% | 60.0% | 66.6% | 67.4% | — |
| Gross profit | $42.7M | $23.4M | $21.1M | $14.3M | — |
| Operating income | -$0.8M | -$2.6M | -$1.2M | -$8.3M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · ETON Stock Surges 108% in Six Months: Here's What You Need to Know
2026-09-28 · Eton Pharmaceuticals Launches Impavido Capsules to Treat Leishmaniasis
2026-09-28 · Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
2026-08-28 · Eton Pharmaceuticals Insider Sold Shares Worth $2,953,572, According to a Recent SEC Filing
2026-08-28 · Jim Cramer Explains Mad Money Caller How to Handle Eton Pharmaceuticals (ETON)
2026-08-27 · Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
2026-08-24 · Eton Pharmaceuticals Insider Sold Shares Worth $1,626,750, According to a Recent SEC Filing
2026-08-24 · TGTX Stock Outperforms 95% of Stocks. Here's Why.
2026-08-21 · Three Biotech Stocks Stick Out With Their Stellar Charts
2026-08-20 · Eton Pharmaceuticals (ETON) Q2 2026 Earnings Call Transcript
2026-08-15 · Is Eton Pharmaceuticals (ETON) Fully Priced On Strong Q2 Results And Raised Guidance?
2026-08-14 · Why Top 3% Biotech Stock, Eton, Just Catapulted To A Record High
Price (daily)
Full chart · RSI · MACD · patterns